Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-tacrolimus versus cyclosporine eye drops in dry eye syndrome
IRCT20181006041253N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Dec 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of tacrolimus and cyclosporine in dry eye syndrome (DED), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Schirmer test, Strip meniscometry and 2 more. Started Dec 2018; status: completed.
02
Drugs
tacrolimuscyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on IRCT20181006041253N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181006041253N1.